Thus, while similar therapeutic approaches should be considered cautiously, intraperitoneal administration of T cells engineered to express a MAGE-A10-specific HLA-restricted T-cell receptor might prove of particular interest in cases of ovarian cancer-associated peritoneal carcinomatosis [59], typically characterized by a paucity of therapeutic options. Here, MAGEA10 is linked to ovarian carcinoma.